Cellstory Liquid Microneedling Treatment Review – Coveteur

For many of us, the thought of needles jabbing into our bodylet alone our facecan make even the bravest of us wince from the mere thought, making many viable aesthetic treatments out of the question. This is not unusualneedle phobia or trypanophobia, if you want to get fancy, is super prevalent, affecting up to 30% of adults. While I dont have a debilitating fear of needles, I love stumbling upon treatments that all of us, if not most, can experience without having, you know, a panic attack. Case in point: liquid microneedling. Dont let the name fool youthere are zero needles involved, but it offers similar benefits that one sees from needle-based treatments.

I happened upon Cellstory during my beauty travels, and I was fascinated by this non-invasive treatment (with little to no downtime) that boasts similar results to a non-ablative laser treatment. Cellstory, the professional treatment in question from Beyond Miracles, is patented with microspears containing 50,000 microneedles derived from freshwater-grown sponges that are applied to the skin (by a professional) through an 8-step facial treatment. ...[S]tep 5 contains the patented Microspear technology, which can be described as liquid microneedles. With the application of medium pressure, the Microspear[s] are delivered into the lower epidermis of the skin, creating tiny microchannels, which allows for better ingredient penetration, explains Dr. Dendy Engelman, MD, FACMA, FAAD, a board-certified cosmetic dermatologist and Mohs surgeon at Shafer Clinic in New York City. In other words, these microspears are small enough to penetrate the skin and work their magic.

Cellstory eliminates the pain, bleeding, swelling and irritation often associated with microneedling. Cellstory helps minimize the appearance of fine lines and wrinkles (specifically around the mouth, eyes, and forehead), acne, pigmentation, and uneven texture. It gives an overall healthy, supple, [and] bouncy glow, adds Dr. Engelman.

I was excited for the opportunity to try Cellstory, especially after waiting some time to schedule it, as I had to make sure that it did not interfere with any treatments or injectables I had previously scheduled. You should avoid Botox and fillers for 14 days before the treatment, and avoid lasers, chemical peels, microneedling and mesotherapy for seven days before, says Dr. Engelman. When the time came, I visited esthetician and founder Taylor Worden at her eponymous skincare oasiswhich I can confirm isin SoHo, New York City, for my Cellstory treatment.

Like any relaxing facial treatment I have gone for, I slipped into something a little more comfortable, wrapped my hair into a top bun, and laid on the esthetician bed. The start of the 8-step treatment was extremely relaxing. First, she applied an amino acid-infused cleanser; second, she swiped a cotton round drenched with a mixture of ginkgo biloba and niacinamide across my face; third, Worden applied an Awake Essense with a brush and let sit on my face for a few minutes; and fourth, she applied an activator ampoule packed with stem cell extract and three growth factors with a brush to my face.

Before I describe step five, the bread and butter of the whole treatment, I want to stress how relaxed and unready I was for what was to come. Worden applied the actual liquid microneedle creampacked with those 50,000 microscopic microneedles (or microspears), yellow calming complex, and growth factors topically through a syringe. She placed small dot-like shapes all over my face.

During step five of the treatment.

My skin immediately following the last step of the treatment.

Then, I vaguely remember her asking me if I was ready. Quickly and in precise circular motions, she massaged it into my skin, and it felt like she was shaving my skin down using sandpaper. The microspears are meant to have a prickly, tingly, and warming effect, but my skin screamed. This continued for several minutes until the cream was completely absorbed into my skin. Though I was very uncomfortable, I knew the cream was working its magic.

The following morning, when I finally touched my face to wash it, I felt the liquid microneedles. It was a sensation I had never experienced before. It almost felt like little pieces of glass lodged into my skin. While this sounds dramatic, its the best way I can describe it; however, it was not painful -just weird. This sensation lasted three days and decreased in intensity with each passing day.

You're advised to cleanse your face lightly after the treatment or until the sensation disappears completely. Following the treatment, for 72 hours, you should avoid retinol, exfoliants (physical or chemical), face oils or oil-based products, heavy sweating (i.e., saunas, heavy exercise), and sun exposure. Additionally, for one week after the treatment, you should avoid chemical peels or lasers, says Dr. Engelman.

My face immediately following the treatment.

My skin the morning after the treatment.

Cellstory is not a one-and-done treatment. We recommend that you initially have four treatments, one week apart," says Dr. Engleman. "After that, we suggest one time per month for maintenance. However, you can see results after just one treatment." There are also two at-home versions of Cellstory, each packed with 10,000 microneedles, compared to the 50,000 in the professional version. The at-home is a great alternative if you dont have access to a provider or want to maintain your treatment results from home.

Id be lying to you if I said I didnt look like a tomato after the treatment. I became the living, breathing version of #tomatogirlsummer. Despite that, my skin looked, in the best way I can describe it, WOW. It was the cleanest and smoothest it has ever looked after a treatment. It was something beyond a miracle (Im sorry - I couldnt resist the pun). In the hours following the treatment, the redness faded. The next morning, my skin looked healthy, glowy, and there wasn't a pore in sight. I was stunned by how a facial gave me better resultsalmost immediatelythan any laser treatment I had ever had.

In the days following the treatment, my skin looked plump and hydrated. Though my skin looked like the perfect canvas for makeup, I opted to go sans cosmetics and take full advantage of my perfect-looking skin.

If youre pregnant or breastfeeding or have any open wounds on your face, you should avoid the treatment. The only skin type that should completely avoid Cellstory altogether, says Dr. Engelman, is someone with severe melasma.

Just an FYI, in case you have a nut allergy: There is a small percentage of macadamia seed oil in step five. The allergy risk is very low, but we recommend spot testing if you have a severe nut allergy, says Dr. Engelman.

Depending on who you see and where you are, the cost of Cellstory can range from $350 to $500. (You can find a full list of providers, here.)

I cannot recommend this treatment enough. It is safe for almost everyone, and the results speak for themselves. Having gone through numerous sessions of both microneedling and radio frequency microneedling, and experiencing post-treatment swelling, redness, and blood, there is absolutely no downside to this treatment. And a reminderzero needles. Just some manageable discomfort. Lets just say Im ready to book my next appointment now.

Go here to read the rest:
Cellstory Liquid Microneedling Treatment Review - Coveteur

Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic … – Cancer Network

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

At an Around the Practice program hosted by CancerNetwork,a panel of experts discussed symptom assessment and the selection of treatment options in patients with chronic graft-vs-host disease (GVHD). They reviewed these topics in the context of a clinical scenario involving a patient with acute GVHD. The panel was led by Nelson J. Chao, MD, MBA, a cellular therapy specialist and stem cell transplant specialist at the Duke Adult Blood and Marrow Transplant Clinic in Durham, North Carolina.

The panelists included Hana Safah, MD, a professor of clinical medicine in the Section of Hematology and Stem Cell Transplantation Program and the Leukemia and Lymphoma Programs at Tulane University School of Medicine in New Orleans, Louisiana; Erin Kopp, NP, the directorof advanced practice and a nurse practitioner at City of Hope Comprehensive Cancer Center in Duarte, California; and Catherine J. Lee, MD, MS, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington.

Chao: Ruxolitinib [Jakafi] is approved as a second-line treatment for GVHD based on the phase 3 REACH3 study [NCT03112603].1,2 If treatment with ruxolitinib fails, what would you do?

Safah: There are options that may also help patients if ruxolitinib fails. Some of my colleagues use ibrutinib [Imbruvica]. Im not as much of a fan of ibrutinib, though it is an option. It has been studied in patients, and it did show benefits, especially if a patient has only skin GVHD. ROCK2 inhibitors are a good third-line option in patients with disease progression following JAK inhibitors. I also continue extracorporeal photopheresis [ECP] in these patients, especially those with skin GVHD.

Kopp: If a patient is starting to show that they may become steroid refractory or dependent, we work them up for clinical trials before we get [to the treatment phase], because clinical trials are an important option to observe. For centers outside of that space, the referral process should start early because clinical trials require screening, slots, and time. We start that concurrently. If we are in a situation where ruxolitinib or any other second-line options are not panning out, we already have the clinical trial potentially available.

Chao: Does anybody have a favorite treatment option?

Lee: Ill still use rituximab [Rituxan] or low-dose weekly methotrexate to see [whether] it helps. Ive seen rituximab work in the very refractory setting, particularly for oral chronic GVHD. I have not had much luck with very advanced ocular or sclerotic chronic GVHD, although there are reports of rituximab having activity in the setting.

Safah: Rituximab can be helpful. I sometimes add rituximab early in patients with severe skin GVHD. Thats one option. Targeting the plasma cells in patients with progression is another. Ive used proteasome inhibitors with minor success. They do not work by themselves, but they can add to the treatments available, whether its rituximab, [ECP], or antithymocyte globulin. However, there is nothing that will always work. Clinical trials are always important to have. [However], when they fail, it becomes a question of: What is available for us, and what can the patient receive? [At this point], it depends on the clinical status, the comorbidities, and the toxicities from the options available.

Chao: Theres the phase 2 AGAVE-201 trial [NCT04710576] with axatilimab that is targeting the monocytes, which is potentially another mechanism.3

Chao: What do you think about this situation?

Lee: I feel horrible for the patient. This is an unfortunate situation, and it is an example of when patients are released back to their homes, they may not be under close supervision before returning with these severe symptoms. The case study brings up a couple questions. When the patient developed acute GVHD, it was treated successfully with corticosteroids. The first questions that come up in my mind are: What was going on with the tacrolimus and sirolimus [Rapamune] at this time? Did the patient just stop taking her medications, or had she been weaned off? Regardless, she does present around month 6 with these GI symptoms, elevated liver function tests, and signs of chronic GVHD as shes reporting tightness around the mouth. This needs to be treated urgently.

At this point, I would have admitted the patient into the hospital and started high-dose steroids, as what was done here. I would have started at 1 mg/kg per day, thinking that this might be acute or chronic GVHD and knowing that some other treatment options take a little longer to take effect. I would have started corticosteroid equivalent at 2 mg/kg per day and watched her carefully. If she had not responded by day 5, I would have added a second-line agent and started tapering off the corticosteroids. I dont find a reason here to increase the steroids to 2 mg/kg after someone doesnt respond to 1.5 mg/kg. The patient was left too long on this 1.5-mg/kg per day dose.

Safah: I agree. I would have been giving the higher dose earlier compared with what was done here. I evaluate these patients very early on. If there is no evidence of response by day 5, or if theyre progressing by day 5 and there is no evidence of response by day 7, I elect to go to a second-line treatment rather than increasing the dose of steroids as such.

Kopp: This is an excellent representation of the type of patients we receive and the questions that often come with them. If theyre not continuing to receive care in the institution in which they underwent a transplant and there are changes to their immunosuppressive regimens, steroids, or presentation of symptoms, we dont always get the full report of what happened. So, patients do show up on my doorstep presenting like this. One thing we need to focus on is how often were monitoring our patients at critical milestones. When you initiate steroids, the concept is that the patient needs to be closely followed for 3,5, or 7 days because we can identifysometimes as early as 3 dayswhether a patient is responding to the corticosteroid dose.

Im hoping this illustrates the challenges that many physicians and other health care professionals have when working with a patient like this. The onus is on everyone who interacts with the patients to say when theres a new symptom and where theres a change in something that we do. Additionally, the patient sometimes must advocate for themselves and say, How can I see you in another week? Or call their transplant physician or the long-term care clinic so were aware of it sooner rather than later.

Organ Involvement With Ruxolitinib and Using Steroids

Chao: Given our earlier discussion, this patients condition is not getting better, and ruxolitinib is the drug we would probably all pick to treat her.

Safah: I agree with you. Ruxolitinib is approved as a second-line therapy in patients who are refractory to steroids. This patient would be a very appropriate candidate for such a treatment.

Chao: Does it matter which organ is involved in terms of outcomes?

Safah: When you look at ruxolitinib in the REACH3 trial, the benefit was seen across all organs. We might combine it with other drugs. We can add rituximab, but we need to be careful [because] it may cause immunosuppression. We need to be careful of the risk of infection, especially when were adding JAK inhibitors. The risk of whether there may be viral reactivation or other infections should be considered when combining ruxolitinib with other immunosuppressants. I prefer to take it slowly. Again, I know benefits have been seen across all organs on the trial.

Lee: We know that in the REACH3 trial for acute GVHD, the responses and the duration of response [DOR] were not so great among those who had severe gastrointestinal involvement. This leads to the unmet need that we are still facing, which is understanding what therapy may fit best for a particular organ. This is an area of research that will help guide treatment for different manifestations of GVHD if we can identify and develop biomarkers.

Chao: Do you taper patients off steroids if you have ruxolitinib as an option? What would you do if someone is refractory?

Lee: We would taper off the steroids in someone who is refractory. This is also very dependent on the institution. Fred [Hutchinson Cancer Center] has a long history of using steroids and being a little slower on the taper, but other institutions may feel comfortable in terms of rapidly tapering off the steroids.

Kopp: My experience is that we are less excited about tapering the steroids even when it seems that patients are refractory. Theres the fear that if you see some effect and then take the steroids away, the disease will flare even more. Theres a reliance on keeping those steroids as you add ruxolitinib or any other agent on top of them. With any oral agent like ruxolitinib, there has been hesitancy to use it with patients who have GI presentations. With the REACH studies, there doesnt seem to be an issue with absorption and utilization unless we know theres a significant issue with a patients absorption. However, there is efficacy to a certain level. Thats where I think we start combining steroids with ruxolitinib, which may give the effect but not the DOR. We may then add another agent if were talking about different organs.

What I have noticed in the [past] 5 years is that the addition of agents has become more intentional. People are looking at the etiology, the drugs mechanism of action, the affected organs, and the research involved. Its a complex process. Before, I would describe practice as a dartboard where you just throw everything at it and see what sticks. Now, there are a lot of ingredients, and were all more experienced with how it will affect the overall outcome.

Chao: Are there any drugs coming down the pipeline that youre excited about?

Lee: The field is exciting to look forward to when it comes to more combinational therapies, as we are seeing that combinations of drugs with different mechanisms of action may help control GVHD and perhaps improve it by targeting different biological pathways. I have used a combination of ruxolitinib and belumosudil [Rezurock], and I know some centers have initiated clinical trials of using these 2 drugs in refractory chronic GVHD.

Safah: In practice, many of us have used ruxolitinib and [belumosudil] together. Some of us have used it in patients who are refractory to one or the other. Ive also used them in patients who have severe chronic GVHD and were not going to be maintained on only 1 drug. Im asking my colleagues now, and Ive requested that we start publishing the data on patients who have received the combination and have done well so that our other colleagues can do the same. Belumosudils safety profile is not bad. On the other hand, the JAK inhibitors do very well, and they have a nice mechanism for controlling inflammation and potentially fibrosis. Adding them together can benefit patients. We can do it in the refractory setting. Maybe we should start looking at earlier lines, and maybe we can skip steroids. Other than that, I think clinical trials will be best, but we dont have many other options at this point.

Kopp: For GVHD, the seeds are planted for early settings in transplant. For posttransplant regimens that include cyclophosphamide, there is a lot of focus on identifying [whether] a patient has acute GVHD or multiple risk factors. Theres been a foundation set with biomarkers. What we do with them next may involve the concept of precision medicine in acute and chronic GVHD to meet the needs of the patient systemically.

Ive also seen a growth in supportive therapy. For the patient, the fact that we can manage these symptoms while were treating the underlying process is probably the biggest development that patients are excited about. If patients have skin that feels like its peeling off and you have 5 more agents now that may treat them topically, thats a huge win as a patient. The same thing applies to oral sloughing. The inability to brush your teeth with toothpaste is something that patients bring to us, as well as needing to wear sunglasses outside at night because their eyes are so dry. The growth in supportive therapy regimens is also something that needs more research because its important to the patients alongside treating the underlying cause.

Read the rest here:
Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic ... - Cancer Network

Molecule discovered that grows bigger and stronger muscles – Earth.com

Over the years, scientists have embarked on anti-aging research to provide drugs and treatments that can slow or reverse aging and treat age-related diseases.Now, scientists at Stanford University have discovered an aging-related protein that can stimulate growth of stronger and larger muscles.

The 15-PGDH protein is the latest discovery by the Stanford scientists, who are working on possible treatments for diminished strength and paralysis due to trauma, heritable neuromuscular diseases, or aging.

Using a mouse model, the researchers injected a 15-PGDH-blocking molecule in older mice. They followed the simulated injuries to the sciatic nerves of the injected mice with treatments.

This led to more prostaglandin E2 (PGE2) production, followed by the growth of stronger and larger muscle fibers in the mice.

By inhibiting the 15-PGDH, also known as gerozyme, the researchers significantly improved the endurance and strength of the muscles grown in the lab.

The researchers found that 15-prostaglandin dehydrogenase (15-PGDH), which accumulates with age and promotes muscle atrophy, markedly increased in denervated mouse myofibers and aggregated in target fibers, hallmarks of chronic nerve damage in human myogenic neuropathies, noted Melissa L. Norton, the editor of the published study.

Treating older mice with chronic muscle denervation with the 15-PGDH inhibitor enhanced the motor neurons and rejuvenated the neuromuscular junctions and function.

This could potentially help older adults who experience increasingly weaker muscles with age and people dealing with muscle-wasting diseases like amyotrophic lateral sclerosis (ALS).

Our data suggests that inhibition of 15-PGDH may constitute a therapeutic strategy to physiologically boost prostaglandin E2, restore neuromuscular connectivity, and promote recovery of strength after acute or chronic denervation due to injury, disease or aging, the researchers noted in their report.

Although this latest study expands on existing evidence of protein regulating muscle function during aging in mice, the researchers have described it as unique.

Study co-author Dr. Helen Blau is the director of the Baxter Laboratory for Stem Cell Biology at Stanford.

This is the first time a drug treatment has been shown to affect both muscle fibers and the motor neurons that stimulate them to contract, speeding up healing and restoring strength and muscle mass, said Dr. Blau.

The Stanford scientists want to build on their findings to see if this mechanism can be transitioned into real-life treatments and therapy.

Our next steps will be to examine whether blocking 15-PGDH function in people with conditions like spinal muscular atrophy, in combination with gene therapy or other treatments, can increase lost muscle strength, said Dr. Blau.

We are also looking at ALS to see if something like this might help these patients. Its really exciting that we are able to affect both muscle function and motor neuron growth.

Weak muscle strength is a huge problem among elders. According to a study by the Centers for Disease Control and Prevention (CDC), five percent of adults aged 60 and over have weak muscle strength, while 13 percent have intermediate muscle strength.

But muscle weakness isnt just a concern for older people. It starts creeping in as early as your 50s and comes with a great economic cost. Weaker muscles reduce the ability to move around, work, and care for oneself. This condition also increases the risk of injuries.

The good news is that science is making promising strides toward addressing this widespread problem. With continued research and advancement, a lasting solution for muscle weakness may be on the horizon.

The study can be found in the journal Science Translational Medicine.

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

Read the original post:
Molecule discovered that grows bigger and stronger muscles - Earth.com

Knight Therapeutics Announces CMED Price Approval of Minjuvi … – GlobeNewswire

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi (tafasitamab) from the Drugs Market Regulation Chamber (CMED). As a result, Knight expects to launch Minjuvi in Brazil in the second quarter of 2024.

In July 2023, ANVISA (Agncia Nacional de Vigilncia Sanitria) granted Market Authorization under their rare disease designation according to Resolution RDC 205/2017 for Minjuvi in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplantation (ASCT).

Diffuse large B-cell lymphoma is a type of aggressive non-Hodgkin lymphoma, with suboptimal efficacy results with standard available therapies for patients who have failed to previous treatments and are not candidates for transplant.

Considering the nature of the disease and the current unmet medical need, there is still space to improve the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in Brazil, said Dr. Danielle Leo, Head of the Hematology Department from Beneficncia Portuguesa Hospital in So Paulo. Minjuvi is an innovative therapy with proven efficacy and safety profile. There is no other effective alternative approved in the country in the second line of treatment for relapsed or refractory DLBCL.

The approval is based on the data from L-MIND, an open label, multicenter, single arm Phase 2 study, that evaluated Minjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL. The study primary analysis results showed an objective response rate (ORR, primary endpoint) of 60%, including a complete response rate (CR) of 43% and a disease control rate (DCR) of 75%.

Were excited to continue to advance the approval of Minjuvi in Brazil, a new treatment option for a current unmet need. We look forward to launching Minjuvi in Brazil and obtaining approval in other key markets in Latin America, said Samira Sakhia, Knight Therapeutics President and CEO.

In September 2021, Knight entered into a supply and distribution agreement with Incyte (NASDAQ: INCY), for the exclusive rights to distribute pemigatinib (Pemazyre) as well as tafasitamab (sold as Monjuvi in the United States and Minjuvi in Europe) in Latin America.

With the price approval Minjuvi will be available for commercialization in the Brazilian market. Knights team is working diligently with physicians, key institutions and payors to ensure patients have access to Minjuvi, said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

About Minjuvi (tafasitamab)

Minjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAbengineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi(tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplantation (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Please see the U.S. full Prescribing Information for Monjuvi for important safety information.

In Europe, Minjuvi(tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials. Its safety and efficacy for these investigational uses have not been established in pivotal trials.

Minjuviand Monjuviare registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuviin the U.S., and marketed by Incyte under the brand name Minjuviin Region Europe, the United Kingdom and Canada. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States.

XmAbis a registered trademark of Xencor, Inc.

About Pemigatinib (Pemazyre)

Pemigatinib is a kinase inhibitor indicated inthe United Statesfor the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The FDA approval in the USA is based on a multicenter, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), that evaluated the safety and antitumor activity of pemigatinib in patients with previously treated, locally advanced or metastatic intrahepatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements, in patients aged 18 years or older with disease progression following at least one previous treatment.

The overall response rate was 36%, with 2.8% of patients having a complete response and 34% having a partial response. Median duration of response was 9.1 months. The most common adverse reactions occurring in 20% or more of patients who received pemigatinib are hyperphosphatemia, alopecia, diarrhea, fatigue, dysgeusia, nausea and stomatitis.

Pemigatinib is also the first targeted treatment approved for use inthe United Statesfor treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

InJapan, pemigatinib is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

InEurope, pemigatinib is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Pemazyre is marketed byIncyteinthe United States,EuropeandJapan.

Pemazyre is a trademark ofIncyte Corporation.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at http://www.knighttx.com or http://www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022 as filed on http://www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

CONTACT INFORMATION:

Continue reading here:
Knight Therapeutics Announces CMED Price Approval of Minjuvi ... - GlobeNewswire

Stem cell therapy Market | Global Upcoming Trends, Growth Drivers, Opportunities and Challenges 2031 – EIN News

PORTLAND, OR, UNITED STATES, April 12, 2023 /EINPresswire.com/ -- The global stem cell therapy market was valued at $205.1 million in 2021, and is projected to reach $928.6 million by 2031, growing at a CAGR of 16.2% from 2022 to 2031.

Stem cell therapy is a form of regenerative medicine that involves the use of stem cells to repair or replace damaged tissues and organs. Stem cells have the unique ability to develop into many different types of cells in the body, which makes them a promising tool for treating a variety of diseases and conditions.

The stem cell therapy market has grown significantly in recent years, driven by a number of factors including an aging population, an increase in chronic diseases, and advancements in stem cell research and technology. The market includes a range of therapies that use stem cells, including hematopoietic stem cell transplantation (HSCT), mesenchymal stem cell therapy (MSCT), and neural stem cell therapy (NSCT), among others.

The market for stem cell therapy is expected to continue to grow in the coming years, with a number of new therapies currently in development and clinical trials. However, there are also a number of challenges and regulatory hurdles that must be overcome in order for stem cell therapy to become widely adopted and accepted as a standard of care.

The report offers an extensive analysis of changing market dynamics, top segments, value chain, competitive landscape, and the Covid-19 pandemic impact. This report provides detailed information for market players, stakeholders, investors, and startups to help them devise strategies for gaining competitive edge and sustainable growth.

: https://www.alliedmarketresearch.com/request-sample/11317

- ?

The Covid-19 pandemic made a negative impact on the stem cell therapy market, owing to disruptions and complexities in supply chain, manufacturing, and logistics processes. The costs and reimbursements related to the stem cell therapy were surged during the pandemic, owing to the lockdown restrictions imposed during pandemic.

The research and development activities were affected during the pandemic due to lockdown restrictions and lack of new investments. Many investors froze the investments for the uncertain period of time to cope up with the economic uncertainties.

Many medical procedures involving stem cell therapy were postponed due to focus on treatment of the Covid-infected patients and shift in hospital resources to Covid wards.

( , , , ) @ https://www.alliedmarketresearch.com/checkout-final/662b31f16976fb52ced0bf81e6e655e7

Based on cell source, the adipose tissue-derived mesenchymal stem cells segment held the highest share in 2021, accounting for more than half of the total share, and is projected to continue its leadership status during the forecast period. However, the bone marrow-derived mesenchymal stem cells segment is expected to manifest the highest CAGR of 16.9% from 2022 to 2031.

Based on application, the cancer segment accounted for the highest share in 2021, contributing to nearly half of the global stem cell therapy market, and is projected to maintain its lead in terms of revenue during the forecast period. Moreover, this segment is expected to manifest the highest CAGR of 16.8% from 2022 to 2031. The report also analyzes the segments including musculoskeletal disorder, wounds and injuries, cardiovascular disease, and others.

Based on type, the autologous transplants segment contributed to the highest share in 2021, holding more than half of the market, and is expected to dominate in 2031. However, the allogeneic transplants segment is projected to grow at the highest CAGR of 16.4% during the forecast period.

Based on region, North America accounted for the highest share in 2021, holding more than half of the global market, and is expected to maintain its dominance by 2031. However, Asia-Pacific is estimated to grow at the fastest CAGR of 19.0% during the forecast period. The research also analyzes regions including Europe and LAMEA.

- https://www.alliedmarketresearch.com/purchase-enquiry/11317

Leading market players of the global steam cell therapy market analyzed in the research include Allele Biotechnology and Pharmaceuticals, Inc., Fujifilm Holding Corporation, Astellas Pharma Inc., Novadip Biosciences, Mesoblast Ltd., Orthofix Holdings, Inc., NuVasive, Inc., Takeda Pharmaceutical Company Ltd., Smith & Nephew plc, and U.S. Stem Cell, Inc.

Grazoprevir Market: https://www.alliedmarketresearch.com/grazoprevir-market-A12479

Medical Waste Management Market : https://www.alliedmarketresearch.com/medical-waste-management-market

:

David Correa

5933 NE Win Sivers Drive#205,

Portland, OR 97220

United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research

David CorreaAllied Analytics LLP+1-800-792-5285email us here

More:
Stem cell therapy Market | Global Upcoming Trends, Growth Drivers, Opportunities and Challenges 2031 - EIN News

Discussing the Future Role of Stem Cell Transplant in Multiple … – Targeted Oncology

Surbhi Sidana, MD

Assistant Professor

Department of Medicine

Division of Blood and Marrow Transplantation & Cellular Therapy

Stanford University School of Medicine

Stanford, CA

DISCUSSION QUESTIONS

SURBHI SIDANA, MD: Im a transplanter, so of course Im biased. What do you think about ASCT based on the results of the DETERMINATION study? Progression-free survival [PFS] was better [but] we dont see an overall survival [OS] difference.1 Did that change how you practice? Do you think it favors doing ASCT early [or shows that since] theres no difference in OS, we should not do the transplant?

ASHKAN LASHKARI, MD: As we incorporate MRD [minimal residual disease] assessment or diagnostic evaluations into our management of our patients with multiple myeloma, we might have a better way of determining whether we need to [transplant] or not. Thats a question that may be answered with the incorporation of MRD, at least in more clinical trials.

SIDANA: You bring up a great point, which is if youre MRD negative after induction, do you need a transplant? I dont think any of these trials answer that question because they did not randomly assign patients who were MRD negative versus MRD positive to ASCT versus no ASCT. I think we need to do these trials in the future.

Some of these trials are starting to happen in small phase 2 trial format. Currently, at least in the IFM 2009 trial [NCT01191060], even if you were MRD negative post hocthey were never randomly assigned based on MRD negativitythe MRD negativity did appear to be somewhat deeper and more sustained with the transplant.2 Those patients had a slightly better PFS. Whether that will hold true for DETERMINATION remains to be seen. I think what the transplant did was make it more sustained, at least in the IFM 2009 trial with 1 year of lenalidomide maintenance, versus no [transplant].

ANDY JANG, MD: I think the DETERMINATION trial is probably dampening the enthusiasm for ASCT for a couple of reasons. If I have a brand-new patient today whom I put on quadruplet therapies, I probably can [avoid transplant] for at least 7 years. Then you have CAR [chimeric antigen receptor] T-cell therapy, which gives you a very high overall response rate [above] 90%.3 The complete response rate is very high. Then you have other targets that are coming and CELMoDS [cereblon E3 ligase modulators]. Based on what I see right now and how effective the quadruplet therapy is, the transplant is probably going to get less emphasized.

SIDANA: Some of our standard-risk patients can get to [7 years on first-line therapy], but a lot of our high-risk patients [will not]. Do you change your practice patterns based on whether they have standard risk versus high risk?

JANG: Yes, of course. Butyou buy them so much [time]. Five years from now, the standard of care for multiple myeloma is definitely going to change. There may be a whole slew of other therapies. Because frontline therapy nowadays is so effectiveIm looking at the transplant value in general and looking at whats coming and whats already here. The CAR T-cell therapy data and even the bispecific antibody data are excellent in triple- or even penta-refractory patients.

SIDANA: Even though I am a transplanter, I hope one day ASCT will go away because every few years you want newer therapies that are less toxic to take over for older therapies. I think of it with a standpoint [where] were still not curing anybody, so lets use all of our treatments, ASCT included. But I hope one day that there is a treatment that can give us similar PFS and hopefully its less toxic and ASCT does go away.

SAM YEH, MD: I like the ASCT arm [in DETERMINATION] because I feel like patients do much better on maintenance than going back on treatment. You get [almost] 20 months extra PFS on the transplant arm based on DETERMINATION.4 Those [nearly] 2 years can give patients a good quality of life versus [if] the disease comes back, and they have lytic bone fractures and quality-of-life issues. There is going to be more toxicity going back on triplets or quadruplets versus when they go on ASCT, then they have a longer PFS and their quality of life may be better.

JANG: If you look at CAR T-cell therapy, it is also one-and-done, the patient has fairly good quality of life, and youre not giving them melphalan. The question is, do you go CAR T-cell therapy or ASCT; they are both one-and-done therapies. But with the transplant, you have to put them on maintenance. So you can argue the other way, [that CAR T-cell therapy is] one-and-done and gives patients a good quality of life.

YEH: CAR T-cell therapy is not indicated in that setting. Its much later.

JANG: That is why I said there is going to be less emphasis on the transplant [in the future] because a CAR T-cell therapy is one-and-done and the patient doesnt have to be on lenalidomide, you dont have to be on dexamethasone, and thats a tremendous selling point for the patient.

SIDANA: Both of you have good points. CAR T-cell therapy is one-and-done, but the indications are completely different. Right now, its fifth line for CAR T-cell therapy, first or second line for ASCT.5

JANG: Thats [true in this] moment in time. We know its not going to [require] 4 lines of therapy [in the future]. Its just because the trial was done that way. When Im going to refer CAR T-cell therapy, Im not going to wait for fourth-line therapies. Im going to start referring them when they have triple or quadruple failures. But right now, I understand the label. Looking atthe future of myeloma therapies, its not going to [require] a fourth-line therapy [before] you refer to CAR T-cell therapy. Its going to change.

SIDANA: I hope its a one-and-done but in all the trials that were designed in early lines, were adding maintenance to the CAR T-cell therapy. Theres a trial coming comparing ASCT to CAR T-cell therapy [CARTITUDE-6; NCT05257083] and theres going to be [lenalidomide] maintenance in the CAR T-cell therapy arm. Im hoping with CAR T-cell therapy we can continue it because patients love the treatment-free interval. They tell me thats the best few months of their life, but because patients still relapse, we are [acting like] ASCT used to be, with no maintenance. But then we added maintenance.

I see whats coming down the pipeline and worry that were going to add maintenance to [CAR T-cell therapy], too, but perhaps not for everybody. We will find out in the future if we need to do that for everybody.

References:

1. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma.N Engl J Med. 2022;387(2):132-147. doi:10.1056/NEJMoa2204925

2. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med. 2017;376(14):1311-1320. doi:10.1056/NEJMoa1611750

3. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8

4. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma.N Engl J Med. 2022;387(2):132-147. doi:10.1056/NEJMoa2204925

5. NCCN. Clinical practice guidelines in oncology. Multiple myeloma, version 3.2023. Accessed March 30, 2023. https://bit.ly/2T0mDYS

Continued here:
Discussing the Future Role of Stem Cell Transplant in Multiple ... - Targeted Oncology

They Drew Out Fluid From My Spine: Rey Mysterio Details How an Aggressive Stem Cell Treatment Saved Him From Voluntary Retirement in 2014 -…

Rey Mysterio had a grand WrestleMania weekend last Saturday, defeating his son Dominik Mysterio after an intense physical bout. Just a day before that big victory, the senior Mysterio also headlined the WWE Hall of Fame 2023.

The 48 year couldnt be more satisfied experiencing two remarkable moments of his storied career back to back. But that moment wouldnt have come if he retired after his humiliating defeat against Samoa Joe at WrestleMania 35. The WWE Hall of Famer once made up his mind about retirement after that match.

However, fortunately, that didnt happen, for the legendary star. He decided to work on his physique which hindered his strength in facing the young stars on the roster. Keeping aside the temporary thought of quitting, the Hall of Famer chose to undergo stem cell treatment that later immensely benefited him in restoring fitness.

ADVERTISEMENT

Article continues below this ad

A wrestlers injury proneness is no secret to fans. But sometimes the injuries are so gruesome that it becomes career-ending, even life-threatening to some extent. Rey Mysterio faced a similar situation back in 2014 when he found his body unfit for a highly physical sport like wrestling. But then it was a costly full-body stem cell treatment that came to his save.

Speaking on the IMPAULSIVE podcast, Mysterio recalled the life-saving therapy he underwent. Detailing the rigorous treatment process, he noted, Every day I ran into stem cells and ever since then you know thats been my final youth. The first couple of times that I did it was actually here and then I got connected to the place in Colombia and they shot me up like full body both knees ankles shoulders biceps. I have carpel tunnel so wrists, my spine, they drew out fluid from my spine.

Rey further reflected on how aggressive and painful this whole treatment process has been for him. It even caused numbness in the whole body for 24 hours after the therapy. But then his temporary discomfort brought him permanent peace and that is something Rey will always be grateful for. But how exactly did the famed wrestler become susceptible to severe injuries that limited his in-ring performances?

ADVERTISEMENT

Article continues below this ad

Despite being a marquee talent Mysterio dealt with numerous injuries throughout his career. Since 2012, there are very few years that didnt bring any injury to him. Especially his knees were dangerously prone to injuries. After handling major knee injuries back in 1997 during his bout with Juventud Guerrera, another grueling one came with a gap of 8 years.

Then the third and the most threatening one came in the 2013 Royal Rumble when he felt like his in-ring stint was about to end. There were many other biceps, and wrist injuries as well, in between these years. The recent injury the master of 619 had to deal with was in 2022 when he suffered a leg injury following his Intercontinental championship match against Gunther.

ADVERTISEMENT

Article continues below this ad

Watch the story: GSP Offered By WWE

However, It seems like the new WWE Hall of Famer is now completely fit and fine to perform at his level best in the squared circle for some more years. What do you make of Mysterios story? Let us know your thoughts in the comments section below.

See the original post:
They Drew Out Fluid From My Spine: Rey Mysterio Details How an Aggressive Stem Cell Treatment Saved Him From Voluntary Retirement in 2014 -...

Novo’s latest deal targets cell therapy for diabetes, obesity – BioPharma Dive

Dive Brief:

Novo, while historically not big on buyouts, has turned to acquisitions over the past couple years to expand its slate of technologies and research programs. In late 2021, it agreed to spend north of $3 billion on Dicerna Pharmaceuticals, a company specialized in so-called RNA interference. And in 2022, it picked up Forma Therapeutics in a $1 billion deal that provided an experimental drug for sickle cell disease in late-stage clinical testing.

Yet, Novos core business still revolves around diabetes and, more recently, obesity. Aided by newer drugs like Rybelsus, Wegovy and, especially, Ozempic, the company last year recorded a 26% increase in net sales and a 34% increase in gross sales.

The new collaboration with Aspect indicates that Novo sees further room to grow in its core areas. Per deal terms, Aspect is eligible to receive as much as $650 million for each resulting product, provided it hits certain developmental, regulatory, commercial and sales goals. Additionally, the biotech would get tiered royalties on future sales of any products.

The deal also further entrenches Novo in the field of cellular medicine. The company established a California-based manufacturing site dedicated to stem cell therapies in 2018. And currently, its researching ways that cell therapies could be used to treat illnesses like Parkinsons disease, chronic heart failure and Type 1 diabetes.

Partnering with Aspect adds an important component to our strategy to develop comprehensive cell therapy products, Jacob Sten Petersen, Novos head of cell therapy research and development, said in a statement.

Novo isnt alone in its pursuits, however. Just last month, Vertex Pharmaceuticals announced that it would be licensing gene editing technology from CRISPR Therapeutics to develop therapies for Type 1 diabetes. The two companies had already been collaborating on a gene editing therapy for sickle cell and another blood disorder, and CRISPR had been working with the biotech Viacyte on its own Type 1 diabetes cell therapy program.

Vertex bought Viacyte last year for $320 million, hoping that the biotechs tools would help accelerate the development of VX-880, an experimental, stem-cell-derived therapy targeting Type 1 diabetes, which Vertex got through its $950 million acquisition of Semma Therapeutics in 2019.

See original here:
Novo's latest deal targets cell therapy for diabetes, obesity - BioPharma Dive

Stem Cell Junk Yards Reveal a New Clue About Aging – WIRED

Robert Signer sees himself as an auto mechanic for human cells. The professor of regenerative medicine at UC San Diego is intrigued by the elusive secrets of the stem cells in our blood. These are a class of rejuvenating entities that replenish supplies of red and white blood cells and platelets. Their job is to help keep our bodies healthy, but as we age their performance dips. When they fail, it can lead to blood cancers, anemia, clotting issues, and immune problems. Signers job is to understand why, and he thinks the answer has to do with how they handle their garbage.

View more

Our cells assemble around 20,000 specific proteins that allow us to do everything from digesting dairy to killing tumors. But the process isnt perfect. When cells mess up, they wind up with whats essentially junk: proteins with missing, extra, or incorrect amino acids in their chains. These can settle into unexpected shapes and malfunctionor worse. They start to stick together, and they form these aggregates, Signer says. Aggregates gum up the machine. Misfolded proteins can actually be toxic. (Researchers have linked Alzheimers disease to gummed-up clumps of protein.)

View more

Most mature blood and immune cells live fast and die hard. They thrive by churning out protein after protein, and mistakes are part of the deal. But life moves slowly for a stem cell. Even modest increases in protein production can be very catastrophic, says Signer. If they make a mistake, waste leads to worse performance, which leads to more waste. So stem cells trying to survive for the long haul must manage their waste like pros.

A healthy stem cell keeps tight control over proteins production and destruction, and this ability to maintain what researchers call protein homeostasis is what fades with age. We think that if we can jump in and prevent this from happening, or improve the ability of stem cells to maintain this protein homeostasis, then we might be able to prevent the decline in stem cell function and the diseases that are associated with those changes, says Signer.

Biologists have long known that stem cells run a tight ship, but not how. So writing in the journal Cell Stem Cell in March, Signers team reported an up-close look at what happens inside the stem cells of young and old mice. (You can't be a good mechanic if you've never looked under the hood, Signer says.)

What they learned was surprising. Biologists had previously assumed that stem cells stay tidy by breaking down waste as fast as it arises, reducing junk proteins into amino acid fodder they can reuse immediately. But Signers group found that blood's stem cells actually squirrel away their misfolded waste and only recycle it when they need it. Scientists had seen this behavior before, but they thought that cells did it in rare cases, when under extreme stress. Signer now believes that healthy stem cells do this as a baselineits a way of pacing themselves in order to maintain control. The mouse data showed that this sophisticated process breaks down with age.

This revelation offers insight into why we age and what critical cellular machinery we must keep running to combat age-related diseases, according to Maria Carolina Florian, a stem cell biologist at the Catalan Institution for Research and Advanced Studies who was not involved in the work. To Florian, it suggests the possibility of creating drugs that can maintain this control for stem cells. It looks particularly important, she says, because of this possibility to be targetedto be able to reverse aging.

Signers lab studied blood stem cells taken from mouse bone marrow. Doctoral researcher Bernadette Chua first extracted marrow from young mice (ages 6 to 12 weeks) and isolated several types of cellsstem cells as well as blood and immune cellsto observe them during an early stage of development. Then, using fluorescent molecules that stick to specific components of the cell, she snooped on each to see how it was managing its trash.

Cells use proteasomes, protein complexes containing enzymes that immediately chew up their misfolded proteins. But Signers lab had previously found that, like neural stem cells, blood stem cells in young mice dont rely on proteasomes very much. In this new experiment, Chua and Signer found that instead of breaking down misfolded proteins right away, stem cells swept them out of the way, collecting them into piles, like mini junk yards. Later, they disintegrated them with a different protein complex called an aggresome. We believe that by storing these misfolded proteins in one place, they're basically holding onto those resources for when they need them, Signer says. Collecting piles of waste may let cells control the pace of their recycling and, as a result, avoid living too fast or too slow.

Yet when Chua next examined marrow from 2-year-old mice, she found a shocking breakdown in this waste management system. Older mice lost their ability to form aggresomes almost entirely at least 70 percent of the stem cells in young mice do it, but only 5 percent in old mice. Instead, old mice swapped to using more proteasomes, a move Signer likens to slapping a spare tire onto an aging car. That was definitely a surprise, Signer says.

This change in waste control machinery is bad news for stem cells. Mice that were genetically engineered to not cache their trash had four times fewer surviving stem cells in their bone marrow in old age. It suggests that those cells are aging, and expiring, faster than they were before.

This distinction between enzymes, wonky as it sounds, could prove crucial for efforts to harness stem cells as anti-aging therapies because it runs counter to previous assumptions. Let's say that you want to engineer a stem cell for regenerative medicine, says Dan Jarosz, a systems biologist from Stanford University who was not involved in the work. Before reading this, I might have thought that a really good thing to do would be to amp up the proteasome activity.

The idea that young, healthy stem cells control the pace of their lives by collecting debris into a storage center, instead of consuming it immediately, is very cool, he continues. This suggests that we need a much more nuanced understanding of how protein quality control functions in aging.

Why older stem cells change their behavior remains an open question. Florian suspects it has something to do with how cells change shape as they age. A healthy cell is typically lopsided, as its contents are sectioned into distinct compartmentsthis asymmetric shape is referred to as being polarized. But stem cells lose their polarity with age, and this affects their ability to shuttle waste to their storage center.

Florians lab is developing drugs that maintain cell polarization. Last year, she reported rejuvenating mouse stem cells with a treatment that tamps down the activity of an overactive enzyme that messes with cell polarity. When transplanted into immunocompromised mice, the stem cell treatment extended their median lifespans by over 12 weeks, or 10 percent. It has a very profound effect on the blood, she says. Basically, you rejuvenate the blood of the mice, and they leave healthier and longer. (Florian serves on the advisory board for rejuvenation start-up Mogling Bio.)

For his part, Signer imagines a drug that maintains the equipment that stem cells use to compost malformed proteinshe doesnt yet know what that would be, but the new experiment gives researchers an idea of where to look. Figuring out that stem cells trash collection system falls apart as the cells age is important, he says, because pinpointing what goes wrong with age gives us an idea of how to target future fixes.

Signer and Florian admit that any drug meant to keep cells young and active carries some cancer risk. Older cells activate genes that prevent tumors and suppress stem cells. Its possible that helping stem cells survive in old age will help cancer cells do the same.

But I also think that there is an alternative possibility happening in parallel, Signer says. Maybe helping stem cells clear their trash slowly and steadily prevents the cascade of effects that lead to problems like cancer, he says: If we can prevent some of those changes, we might be able to prevent multiple types of age-related diseases.

Read more here:
Stem Cell Junk Yards Reveal a New Clue About Aging - WIRED

Regenerative Medicine Market Investments, Share and Revenue Analysis | Latest InsightAce Report – Yahoo Finance

InsightAce Analytic Pvt. LTd.

The global Regenerative Medicine market is estimated to reach over USD 183.08 billion by 2031, exhibiting a CAGR of 15.02% during the forecast period

Jersey City, NJ, April 12, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GlobalRegenerative Medicine Market Size, Share & Trends Analysis Report By Product (Therapeutics, Primary cell-based therapeutics, Stem Cell & Progenitor Cell-based therapeutics), By Therapeutic Category (Dermatology, Musculoskeletal, Immunology & Inflammation, and Oncology)- Market Outlook And Industry Analysis 2031"

The global Regenerative Medicine market is estimated to reach over USD 183.08 billion by 2031, exhibiting a CAGR of 15.02% during the forecast period.

In recent year, it has been determined that regenerative therapies can uniquely change the underlying pathological processes. Trial-stage regenerative medicines offer promising treatments for particular chronic diseases with unmet medical needs. Novartis announced the release of T-ChargeTM in December 2021, a next-generation CAR-T platform that would be used for cutting-edge investigational CAR-T cell treatments.

Free PDF Report Brochure @https://www.insightaceanalytic.com/request-sample/1687

The development of gene-based treatment, which uses targeted DNA delivery as a drug to combat numerous illnesses, results from significant effects in molecular therapeutics. With the restoration of gene function, gene therapy holds great promise for treating cancer and type 1 and type 2 diabetes. Gene-based medicines treat patients with conditions such as cancer, oncology, infectious diseases, cardiovascular disorders, monogenic diseases, genetic disorders, ophthalmological indications, and central nervous system illnesses. These elements have helped the market for regenerative medicine expand.

Recent Developments:

In April 2022, Obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor T therapy being investigated in the ongoing FELIX Phase 2 study of leukaemia, has been given the Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration (FDA). This was announced by Autolus Therapeutics plc.

Story continues

List of Prominent Players in the Regenerative Medicine Market:

AstraZeneca plc;

F. Hoffmann-La Roche Ltd.;

Integra Lifesciences Corp.;

Astellas Pharma, Inc.;

Cook Biotech, Inc.;

Bayer AG;

Pfizer, Inc.;

Merck KGaA;

Abbott;

Vericel Corp.;

Novartis AG;

GlaxoSmithKline (GSK);

Baxter International, Inc.;

Boehringer Ingelheim;

Amgen, Inc.;

Cesca Therapeutics, Inc.;

U.S. Stem Cell, Inc.;

Bristol-Myers Squibb;

Eli Lilly and Company;

NuVasive, Inc.;

Organogenesis, Inc.;

MiMedx Group, Inc.;

Takara Bio, Inc.;

Osiris Therapeutics, Inc.;

Corline Biomedical AB

Get Customized Report @https://www.insightaceanalytic.com/customisation/1687

Regenerative Medicine Market Report Scope:

Report Attribute

Specifications

Market size value in 2022

USD 52.66 Bn

Revenue forecast in 2031

USD 183.08 Bn

Growth rate CAGR

CAGR of 15.02 % from 2023 to 2031

Quantitative units

Representation of revenue in US$ Million, and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends

Segments covered

Product And Therapeutic Category

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Market Dynamics:

Drivers- The ability of adult stem cells to proliferate or self-renew forever and to develop all the cell kinds of the organ from which they originate has propelled research into these cells, with the potential to regenerate the complete organ from a few cells. No embryo must be destroyed in order to produce adult stem cells. Furthermore, medical research on stem cells has been thoroughly examined and attracted much attention. ExCellThera Inc. and Ossium Health recently announced a partnership to explore and advance opportunities to use adult stem cells from deceased donors from Ossium Health's first-ever bone marrow bank in combination with ExCellThera's ECT-001 cell expansion and rejuvenation technology. This collaboration will take place in April 2021. These kinds of developments are anticipated to accelerate market expansion.

Challenges:The market for regenerative medicine is projected to be hampered by a lack of information and moral considerations surrounding the usage of embryonic stem cells for research and development. Since cell therapy is a crucial component of regenerative medicine, it has a significant impact on the market growth rate. One of the leading market inhibitors may be the high cost of investment, which might be followed by problems with assay sensitivity, robustness, and reproducibility; the challenge of culture/propagation; and finally, the challenge of handling.

Regional Trends:Due to the presence of big players, the rapid advancement of technology, significant investments in stem cell and oncology research, and the presence of major players, North America is predicted to have the largest revenue share. The largest market in North America is the United States. In the U.S., numerous stem cell therapies are increasingly being used to treat a growing number of ailments like cancer and diabetes. According to the Heart Disease & Stroke Statistics Fact Sheet 2020, congenital heart abnormalities are predicted to affect at least 40,000 infants annually in the United States.

Enquiry Before Buying @https://www.insightaceanalytic.com/enquiry-before-buying/1687

Segmentation of Regenerative Medicine Market-

By Product-

Therapeutics

Primary cell-based therapeutics

Dermatology

Musculoskeletal

Surgical

Dental

Others

Stem Cell & Progenitor Cell-based therapeutics

Autologous

Allogenic

Others

Cell-based Immunotherapies

Gene Therapies

Tools

Banks

Services

By Therapeutic Category-

By Region-

North America-

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

South East Asia

Rest of Asia Pacific

Read more:
Regenerative Medicine Market Investments, Share and Revenue Analysis | Latest InsightAce Report - Yahoo Finance